Ultime notizie per SI-BONE (NASDAQ:SIBN) Azioni

SI-BONE

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

SI-BONE Inc

SI-Bone (SIBN) has shared an announcement. Daniel Wolf has been elected as a director of the Company by its board, starting from August 5, 2024. He...

SI-Bone Welcomes Daniel Wolf as New Board Member

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>SI-BONE</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/sibn-stock-quote/"><strong>SIBN</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>SI-BONE reported earnings per share of -22 cents. This was above the analyst estimate for EPS of -28 cents.</li><li>The company reported revenue of $39.97 million.</li><li>This was 4.30% better than the analyst estimate for revenue of $38.32 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/sibn-stock-earnings-si-bone-for-q2-of-2024/">SIBN Stock Earnings: SI-BONE Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

SIBN Stock Earnings: SI-BONE Beats EPS, Beats Revenue for Q2 2024

SI-BONE, Inc. (SIBN) Q2 2024 Earnings Call Transcript

Analyst David Turkaly of JMP Securities reiterated a Buy rating on SI-Bone (SIBN – Research Report), retaining the price target of $32.00. David Tu...

Buy Rating Affirmed: SI-Bone's Financial Success and Growth Trajectory Outshine Market Expectations

Analyst David Saxon from Needham reiterated a Buy rating on SI-Bone (SIBN – Research Report) and decreased the price target to $19.00 from $27.00. ...

SI-Bone's Strong Growth and Path to Profitability Affirm Buy Rating

Truist Financial analyst Richard Newitter maintained a Buy rating on SI-Bone (SIBN – Research Report) today and set a price target of $18.00. The c...

Truist Financial Remains a Buy on SI-Bone (SIBN)

Analyst Drew Ranieri of Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report), reducing the price target to $19.00. Drew Ranie...

Buy Rating Maintained for SI-Bone Amid Strong Q2 Performance and Promising Growth Outlook

SI-BONE receives 510(k) clearance and FDA breakthrough device designation

Stocks with three weeks of deteriorating technicals by Piper Sandler

Analyst Drew Ranieri of Morgan Stanley maintained a Buy rating on SI-Bone (SIBN – Research Report), retaining the price target of $19.00. Drew Rani...

Buy Rating Justified: SI-Bone's Growth Potential and Market Expansion Opportunities

ARWR

BPMC

CVBF

ENVX

HIMS

HOMB

INCY

LBRT

MITT

SIBN

SRCE

News

Press Releases

SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024

Earnings

SI-BONE, Inc. Reports Financial Results for the First Quarter 2024

General

SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures

SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024

SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024

SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024

Health Care

SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

Comments

SI-BONE

Notizie

Ultime notizie per SI-BONE (NASDAQ:SIBN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO